Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Rating of “Moderate Buy” by Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $85.3333.

PBH has been the subject of a number of research analyst reports. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Wednesday, September 24th. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Oppenheimer reduced their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares of the company’s stock, valued at approximately $2,539,740. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its holdings in shares of Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after buying an additional 144 shares during the period. Bank of Montreal Can boosted its holdings in Prestige Consumer Healthcare by 2.0% during the second quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock valued at $747,000 after acquiring an additional 182 shares during the period. Profund Advisors LLC grew its position in shares of Prestige Consumer Healthcare by 3.2% in the third quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after purchasing an additional 207 shares during the last quarter. Cerity Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after purchasing an additional 218 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Prestige Consumer Healthcare by 312.5% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 0.5%

PBH stock opened at $61.98 on Friday. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. The company has a market cap of $2.98 billion, a price-to-earnings ratio of 15.38, a PEG ratio of 1.96 and a beta of 0.39. The business has a fifty day simple moving average of $60.70 and a 200-day simple moving average of $68.36. Prestige Consumer Healthcare has a 52 week low of $57.25 and a 52 week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.